Hepatitis E Vaccine Clinical Experience. Mrigendra P. Shrestha

Transcription

1 Hepatitis E Vaccine Clinical Experience Mrigendra P. Shrestha 1

2 Hepatitis E in Nepal 2

3 Hepatitis E in Nepal Most common type of acute viral hepatitis Occurs in annual rainy season outbreaks Responsible for fulminant hepatitis, especially in pregnant women Causes sporadic and epidemic disease Surveillance in military = 2% AR/yr in Kathmandu Valley Major health problem for soldiers 3

4 Study site & population Active duty Nepal Army members Male or female of age 18 years Consenting to participate SEX N MEAN AGE SD MIN MAX F M TOTAL Shree Birendra Hospital, Kathmandu 4

5 Surveillance for disease Military personnel were enrolled from 45 Nepalese Army units Active F/U every other week by a unit health worker Clinic and hospital-based surveillance daily Suspected cases were evaluated with clinical labs (ALT, bilirubin,, with QC by research team) If acute hepatitis suspected, 4 serum specimens (D, 7, 14, 28) and 2 stool specimens (D, 3) were collected These were shipped bi-weekly to Bangkok for serologic and RT- PCR testing All medically significant illness hospitalization These events were reported as Serious Adverse Events 5

6 Examples of hepatitis E in the study 6

7 Hep E Case (1) (Stool samples neg for HEV RNA) Symptoms: A = jaundice, B = fatigue, C = anoreixa D = abdominal discomfort, E = RUQ abdominal pain, F = nausea 7

8 Hep E Case (2) (Serum and stool pos for HEV RNA) Symptoms: A = jaundice, B = fatigue, C = anoreixa F = nausea, G = vomiting 8

9 Hep E Case (3) (Later presentation, brief HEV RNA positivity, lower max ALT but intense jaundice) Symptoms: A = jaundice, B = fatigue, C = anoreixa D = abdominal discomfort, E = RUQ abdominal pain. F = nausea 9

10 Hep E Case (4) (Early presentation, late seroconversion to IgM/Ig, HEV RNA 1 st pos marker) Symptoms: A = jaundice, B = fatigue D = abdominal discomfort E = RUQ abdominal pain 1

11 Hep E Case (5) (Intense jaundice, longer convalescence) Symptoms: A = jaundice, B = fatigue, C = anoreixa E = RUQ abdominal pain, F = nausea G = vomiting 11

12 Hep E Case (6) (Viremia persisting 2 weeks after resolution of symptoms) Symptoms: A = jaundice, B = fatigue, C = anoreixa F = nausea 12

13 Hepatitis E cases: Duration, biochemistries Duration in days Group N Mean SD Min Q1 Median Q3 Max Placebo Vaccine Total Max ALT (U/L) Parameters Placebo Vaccine Total N Mean SD Minimum Q Median Q Maximum Geo. mean Max Bilirubin (mg/dl) No fulminant hepatitis, no deaths Parameters Placebo Vaccine Total N Mean SD Minimum Q Median Q Maximum Geo. mean

14 Diagnoses of hepatotrophic disease in the Total vaccinated cohort Placebo Vaccine Total n n n Clinically-suspected hepatitis E Serologically-confirmed hepatitis A (HAV-IgM) Serologically-confirmed hepatitis B (HBc-IgM) Hepatitis B carrier (HBs-Ag positive but HBc-IgM negative) 2 3,4 2 Serologically-detected hepatitis C (HCV-IgG) Serologically-detected leptospirosis (Lepto-MAT and Lepto-IgM) 6 3,5,6 2 7,8 8 Serologically detected scrub typhus (IgM by PANBIO test & IgM or IgG w. blot) 3 9, Virologically and serologically confirmed hepatitis E One subject = Hepatitis E and acute hepatitis B 3 One subject = Hepatitis E in a HBV carrier (also possible recent leptospirosis infection) 4 One subject = Hepatitis E in a HBV carrier 5 One subject = Hepatitis E in an HCV-exposed subject (also possible recent leptospirosis infection) 6 Four subjects = Hepatitis E in subjects with possible recent leptospirosis infection 7 One subject = Hepatitis E in a subject with possible recent leptospirosis infection 8 One subject = not hepatitis E (Possible recent leptospirosis infection) 9 One subject = Hepatitis E in a subject with possible recent scrub typhus infection 1 Two subjects = Hepatitis E in subjects with possible recent scrub typhus infection 11 One subject = Hepatitis E in a subject with a possible recent scrub typhus infection Most clinically-suspected acute viral hepatitis was hepatitis E; coinfections with other agents were uncommon 14

15 Not hepatitis E cases N = 24 None had definitive serum markers for : HAV, HBV, HCV Scrub typhus, leptospirosis Two cases had HEV infection confirmed by viremia and IgM Both not hepatitis (ALT, bilirubin case def.) Hepatitis E case ascertainment was adequate. Results confirm that hepatitis E is the major cause of acute viral hepatitis among adults in Nepal 15

16 Safety outcomes 16

17 Occurrence of Adverse Events Spontaneous report of any adverse event Reactogenicity subset (N=2) Grade 3 (prevents daily activities) Vaccine 28.% 3.3% Placebo 27.% 3.% Total cohort minus reacto subset (N=18) 25.2% 24.9% Serious adverse events (excluding hep E) Vaccine Reactogenicity subset (N=2) Infections 13.5% 73/135 events Placebo 13.7% 73/137 events Hepatitis E was the most common medically significant illness in the placebo group The next most common illness overall was enteric fever (2.% in vaccine group, 2.4% in placebo group 17

18 Serious Adverse Events (SAE) Category MEDICINE COMMUNICABLE 247 (61.3%) NON COMMUNICABLE 5 (12.4%) Total 297 (73.7%) DEATH 7 (1.7%) DERMATOLOGICAL 5 (1.2%) PREGNANCY 2 (.5%) PSYCHIATRIC 3 (.7%) READMISSION 14 (3.5%) SURGICAL 72 (17.9%) UNDIAGNOSED 3 (.7%) Total 43 (1%) 18

19 Serious Adverse Event: HEV Nov-3 Dec-3 Jul-3 Aug-3 Sep-3 Oct-3 Feb-2 Mar-2 Apr-2 May-2 Jun-2 Jul-2 Aug-2 Sep-2 Oct-2 Nov-2 Dec-2 Jan-3 Feb-3 Mar-3 Apr-3 May-3 Jun-3 Jan-2 Dec-1 Rainy season Rainy season Hospitalized Medically Important Event Death Rainy season Jul-1 Aug-1 Sep-1 Oct-1 Nov-1

20 Communicable diseases among Serious Adverse Events Primary Diagnosis Total % HEPATITIS ENTERIC INFECTION RESPIRATORY TRACT INFECTION VIRAL FEVER DIARRHOEA MALARIA INFESTATION MUMPS URINARY TRACT INFECTION HERPES ZOSTER 2.8 LEPTOSPIROSIS 2.8 OTITIS MEDIA 2.8 CONJUNCTIVITIS 1.4 JAPANESE ENCEPHALITIS 1.4 MEASLES 1.4 RHEUMATIC FEVER 1.4 SEXUALLY TRANSMITTED DISEASE 1.4 Total

21 Summary In Nepal, hepatitis E is the major cause of acute liver disease in adults Active surveillance found a 2-fold 2 higher rate of hepatitis E than expected Annual disease intensity varies, so multi-year evaluation of vaccine efficacy is useful Hepatitis E presents in varied ways RT-PCR (serum) is the preferred diagnostic test Serology can be confirmatory In this cohort, hepatitis E was the most common medically significant diagnosis Safety monitoring required evaluation of many other infectious illnesses Global attention is required for prevention of this disease in order o to reduce socio economic burden and maternal-perinatal mortality in endemic region. 21

22 Bibliography Ashma Rana, Geeta Gurung,, et al. (AOCOG-27), Alrarming rise in deaths from hepatitis in recent 5 years (22-26): 26): A changing pattern of maternal mortality over the last decade 6C-5, Sep 27, Tokyo, Japan Shrestha, M. P., R. M. Scott, et al. (27). "Safety and efficacy y of a recombinant hepatitis E vaccine." N Engl J Med 356(9): Shrestha, S. M. (26). "Hepatitis E in Nepal." Kathmandu Univ Med J (KUMJ) 4(4): Shrestha, K (21). Hepatitis E in the Royal Nepal Army and the Kathmandu valley. MJSBH Platinum Jubilee 257: 1-91 Final Clinical Study Report: A phase II, prospective, Randomized, d, Double- blind, Placebo Controlled, Field Efficacy Trial of a candidate Hepatitis H E Vaccine in Nepal 22

23 Acknowledgement Julie A Pavlin, GEIS-AFRIMS Mammen P Mammen, USAMMDA Robert A Kushner, WRAIR Bruce L Innis, GSK Sanjaya K Shrestha, WARUN Binob Shrestha, WARUN 23